Comparison of the pharmacokinetics and pharmacodynamics of single-dose tenofovir vaginal film and gel formulation (FAME 05)
Journal of Acquired Immune Deficiency Syndromes Feb 04, 2018
Robinson JA, et al. - Despite a reduction in HIV acquisition rates with preexposure prophylaxis with oral tenofovir (TFV) disoproxil fumarate/emtricitabine, poor adherence to and acceptability of daily vaginal gels have led to development of vaginal film formulations to improve adherence and, potentially, to enable episodic use. Researchers, in this work, compared the pharmacokinetics and pharmacodynamics of single-dose tenofovir vaginal film and gel formulation. During the first day after dosing, single-dose tenofovir film showed consistently higher concentrations in plasma and cervicovaginal samples when compared with gel. At 5 hours, single-dose cervical tissue TFV-diphosphate concentrations exceeded steady-state concentrations previously reported with daily oral Truvada dosing. They suggested the utility of tenofovir film as an alternative to tenofovir oral and gel formulations.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries